Top

Clinical Research in Cardiology Supplements

Published in:

Open Access 01-04-2015

Indications for apheresis as an ultima ratio treatment of refractory hyperlipidemias

Authors: Prof. Dr. med. P. Grützmacher, C. Kleinert, C. Dorbath, B. Öhm

Published in: Clinical Research in Cardiology Supplements | Special Issue 1/2015

Abstract

Lipid apheresis is at present well established in routine treatment of diverse hyperlipoproteinemias refractory to conventional dietary and medical regimens, especially in countries with high medical and socioeconomic standards. Severe familial hypercholesterolemia with atherosclerotic vessel disease involving the coronary arteries is the most frequent indication for lipid apheresis as well as homozygous familial hypercholesterolemia before the development of cardiovascular complications.

In hyperlipoproteinemia (a) with progressive vessel disease, lipid apheresis is regularly accepted in Germany. The indication of apheresis in Refsum’s disease and the chylomicronemia syndrome is described.

Cuchel M, Bruckert E, Ginsberg H et al (2014) Homozygous familial hypercholesterolaemia: new insight and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 35:2146–2157CrossRefPubMedCentralPubMed

Raal FJ, Pilcher GJ, Panz VR, van Deventer HE, Brice BC, Blom DJ, Marais D (2011) Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 124:2202–2207CrossRefPubMed

Raal FJ, Santos RD (2012) Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis 223:262–268CrossRefPubMed

Reiner Z et al (2011) ESC/EAS guidelines for the management of dyslipidaemia of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32:1769–1818CrossRefPubMed

Robinson J et al (2014) Odyssey long-term and outcome study, Hotline session 707, ESC Congr. 2014, Barcelona, Spain

Raal FJ, Santos RD, Blom DJ et al (2010) Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 375:998–1006CrossRefPubMed

Cuchel M, Bloedon LT, Szapary PO, Kolansky DM et al (2007) Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 356:148–156CrossRefPubMed

Cuchel M, Meagher E, du Toit Theron H et al (2013) Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 381:40–46CrossRefPubMed

Awan Z, Alrasadi K, Francis GA (2008) Vascular calcifications in homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 28:777–785CrossRefPubMed

10.

Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG et al (2013) Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Eur Heart J 34(45):3478–3490CrossRefPubMedCentralPubMed

11.

Vella A, Pineda AA, O’Brien T (2001) Low-density lipoprotein apheresis for the treatment of refractory hyperlipidemia. Mayo Clin Proc 76:1039–1046CrossRefPubMed

12.

Thompson GR, Catapano A, Saheb S, Atassi-Dumont M et al (2010) Severe hypercholesterolemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. Curr Opin Lipidol 21:492–498CrossRefPubMed

13.

Kamstrup PR, Tybjaerg-Hansen A, Steffensen A, Nordestgaard BG (2009) Genetically elevated lipoprotein (a) and increased risk of myocardial infarction. JAMA 301:2331–2339CrossRefPubMed

14.

Kamstrup P, Benn M, Hansen A et al (2008) Extreme lipoprotein (a) levels and risk of myocardial Infarction in the general population, the Copenhagen City Heart Study. Circulation 117:176–184CrossRefPubMed

15.

Roth EM, Mc Kenney JM, Pharm D, Hanotin C, Asset G, Stein EA (2013) Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 367:1891–1900CrossRef

16.

Jäger B, Richter Y, Nagel D et al (2009) Longitudinal cohort study of the effectiveness of lipid apheresis treatment to reduce high lipoprotein (a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 6:228–237

17.

Leebmann J, Roseler E, Julius U et al (2013) Lipoprotein apheresis in patients of maximally tolerated lipid lowering therapy, Lp (a)-hyperlipoproteinemia an progressive cardiovascular disease: prospective observational multicenter study. Circulation 128:2567–2576CrossRefPubMed

18.

Piolot A, Nadler F, Cavallero E, Coquard JL, Jacotot B (1996) Prevention of recurrent acute pancreatitis in patients with severe hypertriglyceridemia: value of regular plasmapheresis. Pancreas 13:96–99CrossRefPubMed

19.

Ewald N, Kloer HU (2009) Severe hypertriglyceridemia: An indication for apheresis? Atherosclerosis Suppl. 10: 49–52

20.

Gaudet D, Méthot J, Déry S et al (2013) Efficacy and long-term safety of alipogene liparvovec (AAV1-LPLS 447X) gene therapy for lipoprotein lipase deficiency: an open label trial. Gene Ther 20:361–369CrossRefPubMed

21.

Schettler G, Münnich S (1998) Lipidosen oder Lipidspeicherkrankheiten. In: Schwandt P, Richter WO (Hrsg) Handbuch der Fettstoffwechselstörungen. Schattauer, Stuttgart-New York

22.

Baldwin EJ, Gibberd FB, Harley C et al (2010) The effectiveness of long-term dietary therapy in the treatment of adult Refsum disease. J Neurol Neurosurg Psychiatry 81:954CrossRefPubMed

23.

Zolotov D, Wagner S, Kalb K, Bunia J, Heibges A, Klingel R (2012) Long-term strategies for the treatment of Refsum’s disease using therapeutic apheresis. J Clin Apher 27(2):99–105CrossRefPubMed

24.

Percy AK, Wanders RJA, Peterson MC, Firth HV, Hoppin AG (2014) Peroxisomal disorders. UpToDate 1–17

25.

Mösges R, Köberlein J, Heibges A, Erdtracht B, Klingel R, Lehmacher W (2009) Rheopheresis for idiopathic sudden hearing loss: results from a large prospective, multicenter, randomized, controlled clinical trial. Eur Arch Otorhinolaryngol 266(7):943–953. doi:10.1007/s00405-008-0823-5

26.

Klingel R, Fassbender C, Heibges A, Koch F, Nasemann J, Engelmann K, Carl T, Meinke M, Erdtracht B (2010) RheoNet registry analysis of rheopheresis for microcirculatory disorders with a focus on age-related macular degeneration. Ther Apher Dial 14:276–286CrossRefPubMed

Title: Indications for apheresis as an ultima ratio treatment of refractory hyperlipidemias
Authors: Prof. Dr. med. P. Grützmacher
C. Kleinert
C. Dorbath
B. Öhm
Publication date: 01-04-2015
Publisher: Springer Berlin Heidelberg
Published in: Clinical Research in Cardiology Supplements / Issue Special Issue 1/2015
Print ISSN: 1861-0706
Electronic ISSN: 1861-0714
DOI: https://doi.org/10.1007/s11789-015-0070-4

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Indications for apheresis as an ultima ratio treatment of refractory hyperlipidemias

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 1/2015

Extrakardiale Manifestation der Lipoprotein(a)-Erhöhung – Gehäuftes Auftreten von peripherer arterieller Verschlusskrankheit und Stenosen der Arteria carotis

Editorial

Lipoprotein apheresis results in plaque stabilization and prevention of cardiovascular events: comments on the prospective Pro(a)LiFe study

Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease

Lipoprotein(a)—clinical aspects and future challenges

Lipoprotein(a) – Einfluss auf die kardiovaskuläre Manifestation

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page